Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Dose Escalation, Tolerability, Safety and Pharmacokinetics Study of ZG005 in Patients With Advanced Solid Tumors

NCT06233292 is registered in ClinicalTrials.gov with Suzhou Zelgen Biopharmaceuticals Co.,Ltd as lead sponsor.

NCT NCT06233292
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06233292 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Dose Escalation, Tolerability, Safety and Pharmacokinetics Study of ZG005 in Patients With Advanced Solid Tumors
Lead sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase
Phase 1/2
Overall status
Unknown status
Start date
June 17, 2022
Completion date
January 31, 2026
Enrollment
484 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors